Abbott Laboratories announced on 5/14/2019 that it has partnered with the National Institutes of Health to support the agency's BRAIN initiative, which aims to accelerate neuroscience research and advancements. Although Abbott is a major biotech company in the US, it actually lacks patents for technology using artificial intelligence in the neurology field. On the other hand, the NIH has an extensive patent portfolio in the AI Biotech/Diagnostics sector, many of which relate to specific neurological or psychiatric conditions such as Parkinson's disease and epilepsy. Will Abbott realize the value of artificial intelligence in the biotech field through this private-public partnership?
